


**MEDICINE COMPOSITION****Publication number:** JP8325146 (A)**Publication date:** 1996-12-10**Inventor(s):** UENO YASUHIKO; SHODA TOMOAKI; SAITOU NAOHIRO**Applicant(s):** KYOWA HAKKO KOGYO KK**Classification:**

**- international:** A61K9/20; A61K31/00; A61K31/415; A61K45/00; A61K47/12; A61K47/16; A61K47/36; A61P9/00; A61P43/00; A61K9/20; A61K31/00; A61K31/415; A61K45/00; A61K47/12; A61K47/16; A61K47/36; A61P9/00; A61P43/00; (IPC1-7): A61K31/415; A61K9/20; A61K31/645; A61K45/00; A61K47/12; A61K47/16; A61K47/36

**- European:****Application number:** JP19950127786 19950526**Priority number(s):** JP19950127786 19950526**Also published as:** JP4022269 (B2)**Abstract of JP 8325146 (A)**

**PURPOSE:** To obtain a compacted oral administration preparation containing a medicinal substance in a high content, easy in tableting, and excellent in disintegrating, eluting and absorbing properties.

**CONSTITUTION:** 1-80wt.% of a medicinally active ingredient (e.g. thromboxane A2 -antagonizing agent) ground into fine particles having particle sizes of  $\leq 30\mu\text{m}$  by a jet grinding method is mixed with a surfactant (e.g. sodium laurylsulfate) in an amount of 1-2wt.% based on that of the medicinally active ingredient or an organic acid salt (e.g. trisodium citrate) in an amount of 0.5-4wt.% based on the medicinally active ingredient, and subsequently formed into nuclear granules. The granules are mixed with a base agent such as starch partially converted into alpha-starch, and subsequently tableted to obtain the objective medicinal composition.; The starch partially converted into the alpha-starch is compounded in an amount of 1-40wt.% based on the medicinally active ingredient. The thromboxane A2 -antagonizing agent is e.g. 11-[2-(5,6-dimethyl-1-benzimidazolyl)ethylidene]-6,1-dihydrodibenzo[b,e]oxepine-2-carboxylic acid or its salt.

---

Data supplied from the esp@cenet database — Worldwide